Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers
NCT ID: NCT01091220
Last Updated: 2011-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2010-03-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Herbal Supplement on Improving Sperm Virility
NCT07109622
Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo
NCT00631696
CMV IGG Antibodies in Semen as a Predictor for Blood Testis Barrier Damage
NCT05302856
Sperm Preparation Prior to Intrauterine Insemination Study
NCT05693220
Royal Jelly Supplementation in Unexplained Male Infertility
NCT07337265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
0.9% saline
Placebo
2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
Certolizumab pegol
Certolizumab pegol 400 mg
Certolizumab pegol
400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Certolizumab pegol
400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
Placebo
2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Prior treatment with biologic response modifiers within 5 half-lives
* History of trauma or surgery to the pelvis/genital area
* Tests positive for tuberculosis, HIV, Hepatitis B or C
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liège, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-015216-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CR0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.